SCHEMBL10219645

SCHEMBL10219645

NCc1nc2cc(-c3nc4ccccc4o3)ccc2n1C1CCOCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.46
ALDH1A1 P00352 6/20 0.46
NPC1 O15118 5/20 0.46
HPGD P15428 5/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
TP53 P04637 3/20 0.46
HSD17B10 Q99714 3/20 0.46
MET P08581 2/20 0.44
RAB9A P51151 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
ATM Q13315 1/20 0.41
MAPT P10636 2/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
NFKB1 P19838 1/20 0.39
STAT1 P42224 1/20 0.39
GFER P55789 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2688563 0.99 KDM4E (0.46) KDM4EALDH1A1NPC1HPGDSMN1; SMN2
SCHEMBL10219556 0.91 MET (0.43) KDM4EALDH1A1NPC1HPGDSMN1; SMN2
SCHEMBL2687941 0.90 HSD17B10 (0.42) KDM4EALDH1A1NPC1HPGDSMN1; SMN2
SCHEMBL2686894 0.90 MET (0.42) KDM4EALDH1A1NPC1HPGDSMN1; SMN2
SCHEMBL2688562 0.89 MET (0.42) KDM4EALDH1A1NPC1HPGDSMN1; SMN2
SCHEMBL2687131 0.88 MET (0.41) KDM4EALDH1A1NPC1HPGDSMN1; SMN2
SCHEMBL2686456 0.87 CREBBP (0.43) METPDE10A
SCHEMBL2687201 0.87 MET (0.41) KDM4EALDH1A1NPC1HPGDSMN1; SMN2
SCHEMBL2688106 0.85 PDE10A (0.42) KDM4EALDH1A1NPC1HPGDSMN1; SMN2
SCHEMBL2688409 0.85 VSIR (0.39) KDM4EALDH1A1HSD17B10METMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829035-B2 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-09 US disclosed
US-8829035-B2 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-09 US disclosed
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-10 US disclosed
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-10 US disclosed
WO-2010137349-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS 住友化学株式会社 (JP) 2010-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS BDNF, NGF, NTRK2 KDM4E 4538/4885ALDH1A1 1772/4885NPC1 525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.